Physician

Gabriel Pardo, M.D.

According to 2025 Medicare claims, Gabriel Pardo, M.D. (NPI: 1215969605) practices neurology in the Oklahoma City, OK market, with the plurality of this provider's patient population coming from Oklahoma, OK. This provider's primary affiliated billing organization is OKLAHOMA MEDICAL RESEARCH FOUNDATION (NPI: 1851561625; TIN: 730580274) and primary practice location at 73104-5005.

Pardo's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 169 traditional Medicare patients, billed 28,405 HCPCS/CPT codes, and received $1,190,338 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 2,410 prescription claims across 233 beneficiaries totaling $4,107,621 in drug costs, led by Enspryng (Satralizumab-Mwge). DME data shows 23 claims. Open Payments data shows 349 records totaling $1,974,413. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,077,276 and ending at $1,190,338. Concurrently, Part D prescription costs have declined steadily, from $6,700,371 to $4,107,621. In contrast, DME billing represents a smaller volume and declined steadily, from $69,779 to $5,367.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	277	73,311	$1,077,276
2016	279	45,880	$800,126
2017	263	29,793	$1,065,394
2018	262	46,184	$1,597,283
2019	260	55,355	$2,106,987
2020	171	36,098	$1,406,516
2021	210	26,271	$1,166,050
2022	177	27,039	$1,137,616
2023	175	25,532	$1,090,879
2024	169	28,405	$1,190,338

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	282	3,229	$6,700,371
2016	251	3,259	$7,123,731
2017	245	3,061	$6,734,257
2018	262	2,844	$6,756,565
2019	269	2,565	$6,410,564
2020	249	2,467	$6,170,203
2021	231	2,270	$5,216,211
2022	237	2,476	$4,803,787
2023	221	2,504	$4,548,274
2024	233	2,410	$4,107,621

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	37	60	$10,937
2016	37	114	$6,440
2017	30	133	$10,323
2018	12	45	$4,568
2019	N/R	42	$1,910
2020	14	38	$4,851
2021	N/R	29	$4,290
2022	12	19	$985
2023	N/R	15	$905
2024	N/R	23	$1,571

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	30	53	$86
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	153	170	$79
96415	Administration of chemotherapy into vein, each additional hour	29	58	$19
96375	Injection of additional new drug or substance into vein	28	53	$9
J2919	Injection, methylprednisolone sodium succinate, 5 mg	28	896	$0

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Enspryng	Satralizumab-Mwge	23	1,166	$719,956
Copaxone	Glatiramer Acetate	92	2,630	$542,621
Mayzent	Siponimod	44	1,500	$493,776
Aubagio	Teriflunomide	38	1,440	$450,702
Kesimpta Pen	Ofatumumab	38	1,200	$365,926

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0635	Patient lift, electric with seat or sling	Y	N/R	12	$1,058
E0260	Hospital bed, semi-electric (head and foot adjustment), with any type side rails, with mattress	Y	N/R	11	$513

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	259	$206,943	EMD Serono, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	90	$1,767,471	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Gabriel Pardo, M.D.?

Tedicare shows public-source Medicare data for Gabriel Pardo, M.D. (NPI 1215969605), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Gabriel Pardo, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Gabriel Pardo, M.D.?

Gabriel Pardo, M.D. is linked to OKLAHOMA MEDICAL RESEARCH FOUNDATION (billing NPI 1851561625) in the available physician profile data.

Does Gabriel Pardo, M.D. have Open Payments data?

Gabriel Pardo, M.D. has 349 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.